Abbott Laboratories plans to spin off its pharmaceutical unit in an attempt to command a higher valuation for its remaining businesses.
Under the plans, the company’s proprietary drug unit, responsible for approximately 45% of Abbott’s revenue, will be separated into a new company with publicly traded stock distributed to Abbott shareholders as a tax-fee transaction.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Richard Gonzalez will head the new unit, whereas the rest of Abbott – including diagnostics, devices, nutritional and branded-generic businesses – will retain the Abbott name.
The move comes after Abbott executives became worried that competitive threats for the company’s biggest selling drug, the anti-inflammatory Humira, were overshadowing separate Abbott businesses which were recording strong sales growth.
